Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sulolizumab plus TP regimen for unresectable esophageal squamous cell carcinoma (real-world study)
ChiCTR2400086307Phase 4Not yet recruiting
- Sponsor
- Xijing Hospital
- Start
- Jun 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of serplulimab in Esophageal Squamous Cell Carcinoma (ESCC), sponsored by Xijing Hospital. Primary endpoint: Safety. Planned start Jun 2024; status: not yet recruiting.
02
Drugs
serplulimab
03
Conditions
Esophageal Squamous Cell Carcinoma (ESCC)
Beyond the preview
Go deeper on ChiCTR2400086307.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400086307.